Quick Takeaways
- T. Rowe Price Investment Management, Inc. filed SCHEDULE 13G/A for APOGEE THERAPEUTICS INC COMMON STOCK (APGE).
- Disclosed ownership: 17%.
- Date of event: 31 Mar 2026.
T. Rowe Price Investment Management, Inc. - 31 Mar 2026 SCHEDULE 13G/A Report for APOGEE THERAPEUTICS INC COMMON STOCK (APGE)
- Filing Manager
- T. Rowe Price Investment Management, Inc.
- Reporting Manager
- T. Rowe Price Investment Management, Inc.
- Security
- APOGEE THERAPEUTICS INC COMMON STOCK
- Symbol
- APGE
- Shares outstanding
- 61,257,262 shares
- Disclosed Ownership
- 10,291,220 shares
- Ownership
- 17%
- Form type
- SCHEDULE 13G/A
- Filing time
- 08 Apr 2026, 15:26:15 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 06 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"T. Rowe Price Investment Management, Inc. disclosed 17% ownership in APOGEE THERAPEUTICS INC COMMON STOCK (APGE) on 31 Mar 2026."
What Changed
- Previous schedule filing date: 06 Mar 2026.
- Current filing was accepted on 08 Apr 2026, 15:26.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17% | 10,291,220 | 9,762,311 | 0 | Ellen York | Vice President |